Top Page
HeraMED Ltd.
(Sydney:HMD)
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
HeraMED Ltd. Business Overview & Revenue Model
HeraMED Ltd. Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 0.00 | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | |||||
| Total Assets | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 0.00 | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 215.21K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 621.27K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | |||||
| Free Cash Flow | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
HeraMED Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.31M | -2.88 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$33.22M | -7.32 | -58.27% | ― | -7.20% | 28.70% | |
45 Neutral | AU$38.98M | -8.14 | -513.22% | ― | -34.06% | 75.47% | |
39 Underperform | AU$3.12M | -2.26 | -218.52% | ― | -30.80% | -38.95% | |
37 Underperform | AU$13.97M | -0.99 | -1476.79% | ― | -2.82% | 32.47% |
HeraMED Ltd. Corporate Events
HeraMED Ltd has lodged its updated corporate governance statement for the year ended 31 December 2025, confirming compliance with ASX Listing Rules that require disclosure of how it adheres to the ASX Corporate Governance Council’s recommendations. The company has outlined that it follows key governance practices, including a formal board charter, due diligence on director and executive appointments, written agreements for directors and senior executives, and direct board accountability for the company secretary, reinforcing its governance framework and transparency for shareholders.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has reported a 10.3% decline in revenues from ordinary activities to $431,605 for the year ended 31 December 2025, while its net loss after tax narrowed by 24.8% to $4.13 million compared with the prior year. The company did not declare any dividends for the current or previous financial periods, and net tangible assets per share fell from 0.23 cents to 0.11 cents, although its audited financial statements received an unmodified opinion, indicating compliance with accounting standards and no material audit issues.
The contraction in revenue alongside a reduced loss suggests HeraMED has made some progress in cost control or restructuring, but it continues to operate at a significant loss, which may weigh on investor sentiment and its capacity to fund growth organically. The decline in net tangible assets per ordinary security highlights ongoing balance sheet pressure, potentially affecting future capital-raising dynamics and valuation, even as the clean audit opinion provides a measure of assurance on the reliability of its reported financial position.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED has released an investor presentation outlining its position as a leader in AI-enabled women’s health, leveraging an FDA-cleared device to deliver solutions from pregnancy through to chronic care. The update is intended to inform investors about the company’s strategic focus on proprietary technology and data-driven care models, which aim to strengthen its market positioning in the growing digital and remote healthcare sector while underlining its ambition to scale within women’s health services.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has called an Extraordinary General Meeting for 26 March 2026 in Hawthorn East, Victoria, and will provide the Notice of Meeting primarily via electronic distribution in line with updated provisions of the Corporations Act. The company is encouraging shareholders to participate either in person or by lodging proxy votes online, by post or by email, with all resolutions to be decided by poll.
Shareholders are also being reminded of their rights to elect how they receive company documents, including the option to receive communications electronically, in hard copy, or to opt out of certain reports. This move toward digital communication is positioned as a more efficient and sustainable way to engage investors, while ensuring that those who prefer physical documents can update their preferences through the share registry portal.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED has appointed U.S. healthcare leader Dr Adam Myers as Chairman of its Commercial Scientific Advisory Board, adding significant clinical and executive expertise from major health systems, payer organisations and digital health enterprises to support the HeraCARE maternity platform. His role will span U.S. market expansion, commercial and reimbursement strategy, clinical governance and AI-enabled predictive maternity care, strengthening HeraMED’s credibility with health systems and payers and supporting faster integration and commercialisation of HeraCARE in the U.S. market.
Dr Myers’ background includes senior roles at Telus Health, Cleveland Clinic and Blue Cross Blue Shield Association, where he influenced care delivery for more than 115 million Americans. His combination of frontline obstetric experience and system-level transformation expertise is expected to help HeraMED refine health-system integration, validate its predictive models and advance value-based care pathways, potentially accelerating adoption and improving outcomes for clinicians, payers and expectant mothers.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has applied to the ASX for quotation of 2,150,000 new fully paid ordinary shares under its issuer code HMD, with an issue date of 4 February 2026. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, will expand the company’s quoted capital base and may marginally enhance its market liquidity for existing and prospective shareholders.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has issued 41,300,685 fully paid ordinary shares on 4 February 2026, in line with a prior capital-related announcement and a corresponding Appendix 2A filing. The company confirmed the new shares were issued without a prospectus under the relevant Corporations Act provisions and stated it remains compliant with its continuous disclosure and financial reporting obligations, with no excluded information outstanding, providing regulatory clarity and transparency for existing and new shareholders regarding the expanded capital base.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has applied to the ASX for quotation of 41,300,685 new fully paid ordinary shares, to be traded under its existing code HMD. The issuance, tied to previously announced transactions, will expand the company’s quoted share base, potentially affecting liquidity and ownership structure as these new securities commence trading on 4 February 2026.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED reported a pivotal December 2025 quarter as it accelerated its US push through two significant commercial agreements: a deal with Philips’ US subsidiary to jointly offer an integrated digital maternity care solution to American hospitals, and a pilot deployment with Florida-based health system Lee Health to roll out its HeraCARE platform across prenatal and postpartum care, including Epic EMR integration and evaluation of clinical and operational outcomes. The company also strengthened its regulatory positioning with Australian Class IIb approval for its HeraBEAT device, advanced platform, data and AI initiatives supported by an expanding dataset of over 167,000 maternal vital measurements, reduced operating cash outflows to their lowest level since 2020 through restructuring, and bolstered its balance sheet via a $3.2 million capital raise to fund near-term US deployments, collectively underpinning a capital-light, scalable commercialisation strategy and enhancing its appeal to hospital partners and investors.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has secured firm commitments to raise A$3.2 million through a two‑tranche placement of 80 million new shares at A$0.04 each, a roughly 7% discount to its last closing price, with support from new institutional and sophisticated investors as well as existing shareholders. The funds will be used to bolster working capital and accelerate the commercial deployment, pilots and integration of its HeraCARE digital maternity platform into major health systems, private clinics and multiple partner platforms in the U.S., Australia and Europe, building on initial commercial agreements with Lee Health and Philips and reinforcing the company’s push for broader scale and stronger market positioning in women’s digital health.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Ltd has requested and been granted a trading halt on its ordinary shares on the Australian Securities Exchange, effective 22 January 2026, while it prepares a market announcement regarding a material proposed capital raising. The halt, which is intended to help the company manage its continuous disclosure obligations and maintain an orderly market in its securities, will remain in place until the earlier of the start of trading on 27 January 2026 or the release of the capital-raising announcement, signaling a potentially significant funding move that could impact existing shareholders and the company’s capital structure.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Limited has appointed William Buck Audit (Vic) Pty Ltd as its new external auditor following the resignation of BDO Audit Pty Ltd, after a competitive tender process, with the appointment to be put to shareholders for ratification at the company’s 2026 Annual General Meeting. The company has also strengthened its governance framework by appointing Stephanie Vipond of Bio101 Financial Advisory as Joint Company Secretary alongside Cameron Jones, with both now responsible for ASX communications, underscoring HeraMED’s focus on compliance and corporate oversight as it advances its digital maternity care platform.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
HeraMED Ltd has applied to the ASX for quotation of 27,150,000 new ordinary fully paid shares under its ticker HMD, following the exercise or conversion of existing options or other convertible securities. The enlarged pool of quoted securities increases the company’s tradable equity base, potentially affecting liquidity and ownership structure, and marks a notable capital-related move for stakeholders to monitor in terms of future financing flexibility and market valuation.
HeraMED Limited announced an upcoming investor update webinar to discuss recent partnerships with Royal Philips and a pilot launch with Lee Health. The webinar will feature discussions on the company’s recent activities and future outlook, providing stakeholders an opportunity to engage with the leadership team.